Lionheart Health Files Patent for Bioelectric-Enhanced Klotho Nanoflowers Targeting Aging Reversal

Lionheart Health, Inc. has filed a non-provisional U.S. patent covering its Bioelectric-Enhanced Klotho Nanoflowers platform, designed for aging reversal and healthspan extension. The system integrates nanoflower-format nanoparticles, bioelectric signaling sequences, and Klotho-modulating biologics to target cellular and mitochondrial drivers of aging. According to Howard J. Leonhardt, Founder and CEO, this represents the convergence of bioelectric signaling, nanomedicine, and Klotho modulation, aiming to reverse biological age at the cellular level safely and non-invasively.

The nanoflowers are engineered to upregulate Klotho, a longevity-associated protein linked to improved brain, kidney, cardiovascular, and metabolic health, while restoring mitochondrial function by enhancing ATP production and reducing oxidative stress. They deliver targeted bioactive agents like peptides, plasmids, mRNA, and CRISPRa activators, acting as nanozyme catalysts that reduce reactive oxygen species and improve cellular resilience. These nanoparticles respond to Lionheart's proprietary bioelectric stimulation sequences, which increase cellular uptake, activate intracellular pathways, and amplify biological performance. Bioelectric stimulation opens ion channels, improves endocytosis, directs nanoflowers toward mitochondria, and triggers therapeutic payload release, with neither component alone producing the full Klotho-enhancing effect, demonstrating a combined therapeutic benefit.

Dr. Leslie Miller, Chief Medical Officer, stated that bioelectric-enhanced Klotho nanoflowers provide a programmable, multi-modal tool to address root causes of aging, such as declining energy production, rising inflammation, and loss of regenerative capacity. The platform is designed for system-wide healthspan improvement, including mitochondrial biogenesis, reduction of cellular senescence, and stabilization of biological age. It builds on Klotho's recognition as a promising longevity molecule, with decreased levels associated with accelerated aging, cognitive decline, and other health issues, while increasing expression has shown benefits in preclinical models.

The patent filing adds to Lionheart Health's intellectual property portfolio, which spans bioelectric-controlled protein expression, stem-cell mobilization, mitochondrial restoration, Klotho-based therapies, and regenerative platforms. Optional components include closed-loop adaptive control using sensors to adapt stimulation patterns, and multi-modal integration with red light, PEMF, and regenerative support. Lionheart is preparing for expanded clinical evaluation through its network of Lionheart Longevity & Wellness Licensed Clinics and plans to integrate the technology into its XPRIZE Healthspan competition program. This development positions the company as a leader in healthspan technologies, with potential implications for advancing non-invasive longevity treatments globally.